Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S331000, C530S384000, C424S094640
Reexamination Certificate
active
06858587
ABSTRACT:
The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
REFERENCES:
patent: 6106830 (2000-08-01), Li
patent: 6268163 (2001-07-01), Kongsbak et al.
patent: WO 9405328 (1994-03-01), None
patent: WO 9427631 (1994-12-01), None
patent: WO 9903498 (1999-01-01), None
patent: WO 9916789 (1999-04-01), None
patent: WO 0105353 (2001-01-01), None
patent: WO 0130333 (2001-05-01), None
Mueller et al. J. Clin. Invest. 101(7):1372-1378 1998.*
Kulik et al. Molecular and Cellular Biology 17:1595-1606 1997.*
Versteeg et al. J. Biol. Chem. 275:28750-28756 2000.*
Bromberg, M. et al. PNAS 92(18): 8205-8209 1995.*
Siegbahn, A. Haemostasis 30(suppl 2):41-47 2000.*
Cooper, Geoffrey M.,The Cell, Part IV, Chapter 13, 2ndEdition, BU 2000.
Eastman, Alan & Rigas, James R., Semin Oncol, vol. 26 (5 suppl. 16), pp. 7-16, dis. 41 & 42 (Oct. 1999).
Héron-Milhavet et al., J. Biol Chem, vol. 276 (19), pp. 18185-18192 (May 25, 2001).
Korsmeyer, Stanley J., Cancer Res., vol. 59 (7 suppl.), pp. 1693s-1700s (Apr. 1, 1999).
Li et al., Arterioscler Throm Vasc Biol., vol. 23 (12), pp. 2178-2184 (Dec. 2003).
Lopaczynski, Wlodzimierz, Acta Biochim Pol, vol. 46 (1), pp. 51-60 (1999).
O'Connor et al. Biochem Soc Trans, vol. 28 (2), pp. 47-51 (Feb. 2000).
Platanias, Leonidas C., Blood, vol. 101 (12), pp. 4667-4679 (Jun. 15, 2003).
Satymoorthy et al., Cancer Res., vol. 61 (19), pp. 7318-7324 (Oct. 1, 2001).
Shack et al., Mol Cell Biol., vol. 23 (7), pp. 2407-2414 (Apr. 2003).
Versteeg et al., Carcinogenesis, vol. 24 (6), pp. 1009-1013 (2003).
Versteeg et al., J. Biol. Chem., vol. 277 (30), pp. 27065-27072 (2002).
Versteeg et al., Oncogene, vol. 23 (2), pp. 410-417 (2004).
Versteeg et al., Thromb Haemost, vol. 86 (6), pp. 1353-1359 (Dec. 2001).
Kawada et al., Japanese Journal of Clinical Hematology, vol. 30, No. 11, pp. 1982-1986 (1989) (translation).
Takeya et al., Thrombosis and Apoptosis, vol. 45, No. 7, (1997) Retrieved from the Internet (translation).
Walther et al., Archiv Fur Klinische Medizin, vol. 215, pp. 161-173 (1968) (translation).
Libby et al., Current Opinion in Lipidology, vol. 7, No. 5, pp. 330-335 (1996).
Bromberg et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp. 8205-8209 (1995).
Greeno et al., Laboratory Investigation, vol. 75, No. 2, pp. 281-289 (1996).
Kockx et al., Circulation, vol. 102, No. 13, p. e99 (2000).
Petersen Lars Christian
Sorensen Brit Binow
Bork Richard
Carlson Karen Cochrane
Desai Anand
Green Reza
Novo Nordisk Pharmaceuticals, Inc.
LandOfFree
Use of tissue factor agonist or tissue factor antagonist for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tissue factor agonist or tissue factor antagonist for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tissue factor agonist or tissue factor antagonist for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486662